<DOC>
	<DOCNO>NCT01509118</DOCNO>
	<brief_summary>Arterial venous thromboembolism represent one common preventable health problem . Patients undergo surgery , especially hip fracture surgery high risk deep vein thromboembolism ( VTE ) without thromboprophylaxis . In absence prophylaxis , incidence fatal pulmonary embolism ( PE ) Hip Fracture Surgery ( HFS ) reportedly 4 % -12 % . Provision thromboprophylaxis patient undergo HFS recommend .</brief_summary>
	<brief_title>Rivaroxaban Safety Profile Prophylaxis Venous Thromboembolism After Hip Fracture Surgery</brief_title>
	<detailed_description>Rivaroxaban first agent new class drug act direct factor Xa inhibitor oral bioavailability . Highly selective inhibition factor Xa rivaroxaban expect inhibit amplified burst thrombin generation may result effective inhibition thrombus formation favorable safety profile . In Thailand rivaroxaban indicate prevention VTE patient undergo major orthopedic surgery lower limb include surgery hip fracture . There limited number observational study rivaroxaban thromboembolism hip fracture surgery approve indication country thromboprophylaxis hip knee arthroplasty . The broad indication high number hip fracture surgery Thailand allow u explore pattern safety profile particularly bleeding complication risk factor patient receive rivaroxaban thromboprophylaxis hip fracture surgery .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Fractures , Open</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>At least 50 year old men postmenopause woman Patients , undergo standard surgery fracture upper third femur , include femoral head , neck , trochanteric subtrochanteric fracture surgery plan within 7 day admission Patients , eligible thromboprophylaxis . Such patient enrol physician 's decision prescribe rivaroxaban thromboprophylaxis make . The decision totally base standard medical practice . Patients , agree participate , return followup visit , sign inform consent participate study . Trauma affect 1 organ system Pathological fracture secondary malignant disease Clinically significant bleed exclude drainage Documented congenital acquire bleed disorder Patients , contraindication thromboprophylaxis contraindication take rivaroxaban accord FDAapproved product label Patient oral anticoagulation therapy past 7 day Pregnancy breastfeed Patients simultaneously participate different study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>